Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 124 Dvora Hanevi'a St TEL AVIV-YAFO 6944020 |
Tel: | 1-267-4684475 |
Website: | https://www.tevapharm.com |
IR: | See website |
Key People | ||
Richard D. Francis President, Chief Executive Officer | David Matthew Stark Executive Vice President, Chief Legal Officer | Eliyahu Sharon Kalif Chief Financial Officer, Executive Vice President |
Galia Inbar Chief Human Resource Officer and Corporate Affairs, Executive Vice President | Richard Daniell Executive Vice President - European Commercial | Eric Drape Executive Vice President - Global Operations |
Christine Fox Executive Vice President - U.S. Commercial | Eric A. Hughes Executive Vice President, Global R & D, Chief Medical Officer | Mark Sabag Executive Vice President - International Markets Commercial | Eli Shani Executive Vice President - Global Marketing and Portfolio |
Business Overview |
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. |
Financial Overview |
For the fiscal year ended 31 December 2023, Teva Pharmaceutical Industries Ltd (ADR) revenues increased 6% to $15.85B. Net loss decreased 77% to $559M. Revenues reflect North America segment increase of 9% to $8.12B, Europe segment increase of 7% to $4.84B, International Markets segment increase of 3% to $1.96B. Lower net loss reflects North America segment income increase of 20% to $2.4B. |
Employees: | 35,001 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $32,596M as of Dec 31, 2023 |
Annual revenue (TTM): | $15,846M as of Dec 31, 2023 |
EBITDA (TTM): | $4,803M as of Dec 31, 2023 |
Net annual income (TTM): | -$559.00M as of Dec 31, 2023 |
Free cash flow (TTM): | $842.00M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $16,607M as of Dec 31, 2023 |
Shares outstanding: | 1,120,992,397 as of Feb 18, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |